Ampio provides update on clinical trials for Ampion treatment of COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More

Tuesday January 5, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, COVID-19

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More

Wednesday November 11, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, Michael Macaluso, COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hasbegun recruiting and enrolling patients in a Phase Imulti-center, randomized, controlled trial for a total of 40... Read More

Thursday October 29, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS

Ampio Pharmaceuticals appoints Dan Stokely CFO

Ampio Pharmaceuticals appoints Dan Stokely CFO

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common... Read More

Thursday July 11, 2019 0 comments Tags: Englewood, Ampio Pharmaceuticals, Dan Stokely, Michael Macaluso

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More

Friday December 15, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion